Haloperidol Bp Teva

Haloperidol Bp Teva is a prescription medication that contains the active ingredient haloperidol, a butyrophenone antipsychotic. It is supplied in oral dosage form and is marketed in the European Union. The product is intended for use under medical supervision for conditions that require dopamine D2 receptor blockade. Haloperidol Bp Teva is a generic version of haloperidol without a specific brand name or label for prescribing.

Haloperidol Bp Teva is indicated for several psychiatric and neurologic conditions where dopamine antagonism is required, and it may be prescribed by qualified healthcare professionals as part of a treatment plan.

- Schizophrenia, including both acute episodes and long‑term maintenance therapy to reduce positive symptoms such as hallucinations and delusions. - Acute psychotic exacerbations of mood disorders or brief psychotic disorder, where rapid symptom control is desired. - Tourette syndrome, particularly when motor and vocal tics are severe enough to interfere with daily functioning. - Severe agitation or aggression in inpatient or emergency settings, often as a short‑term measure while other interventions are initiated. - Adjunctive therapy for other psychotic conditions, such as schizoaffective disorder or brief psychotic reactions, when clinicians deem dopamine blockade beneficial.

Haloperidol Bp Teva may cause a range of adverse effects, some of which are dose‑related and reversible, while others require prompt medical attention.

Common: - Drowsiness or sedation, especially when therapy is initiated or dose is increased. - Extrapyramidal symptoms such as tremor, muscular rigidity, or akathisia that may affect mobility. - Dry mouth and constipation, reflecting anticholinergic activity. - Blurred vision or dizziness, which can impair driving or operating machinery.

Serious: - Tardive dyskinesia, a potentially irreversible movement disorder that may involve facial grimacing, tongue protrusion, or limb chorea. - Neuroleptic malignant syndrome, a rare but life‑threatening reaction characterized by high fever, severe muscle rigidity, altered mental status, and autonomic instability. - Significant cardiac arrhythmias, including QT interval prolongation that can predispose to torsades de pointes.

When prescribing Haloperidol Bp Teva, clinicians should evaluate patient history and monitor for specific safety concerns to minimize risk.

- Assess for a history of cardiovascular disease, especially prolonged QT interval or arrhythmias. - Use caution in patients with Parkinson’s disease, severe depression, or a predisposition to extrapyramidal reactions. - Evaluate liver and kidney function before initiating therapy and adjust dose in hepatic or renal impairment. - Monitor for signs of neuroleptic malignant syndrome during the first weeks of treatment. - Avoid abrupt discontinuation; taper the dose gradually to reduce withdrawal or rebound psychosis. - Consider pregnancy and lactation status; the safety profile in these populations is not well established.

Haloperidol Bp Teva can interact with other medications that affect the central nervous system or cardiac conduction, requiring careful review of a patient’s drug regimen.

Avoid: - Concurrent use with other potent dopamine antagonists or high‑dose antipsychotics, which may increase extrapyramidal risk. - Co‑administration with drugs that markedly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics, or antimalarials). - Combining with strong CYP3A4 inhibitors such as ketoconazole or clarithromycin, which can raise haloperidol plasma levels.

Use with caution: - Use cautiously with CNS depressants (e.g., benzodiazepines, opioids, or alcohol) due to additive sedation. - Monitor closely when given with antihypertensive agents, as haloperidol may enhance orthostatic hypotension. - Adjust dose when prescribed alongside CYP2D6 substrates or inducers, because metabolic changes can alter drug exposure.